

**Original article:**

## **Influence of hypothyroidism on biochemical markers of liver function test: a cross sectional study**

**Dr. Naba kumar kalita\*, Dr. Runi Devi\*\* Dr. Shamim Ahmed\*\*\***

\*Post graduate trainee, Department of biochemistry, Gauhati Medical College & Hospital

\*\*Professor & Head, Department of biochemistry, Gauhati Medical College & Hospital

\*\*\* Post graduate trainee, Department of biochemistry, Gauhati Medical College & Hospital

Corresponding author: Dr. Naba kumar kalita

---

### **Abstract:**

**Introduction:** Normal level of thyroid hormone is important for normal hepatic function as it maintain the metabolism of bilirubin by playing a role in the enzymatic activity of glucuronyltransferase and by regulating the level of ligandin. The liver in turn glucuronidates and sulphates the thyroid hormone, excretes into bile and regulates their systemic endocrine effects. Therefore hepatic dysfunction is commonly observed in patients with thyroid disease. Aim was to determine the biochemical markers of Liver Function Test (LFT) in patients with hypothyroidism and their possible correlation with thyroid profile.

**Methods:** Thyroid profile and liver function test (LFT) were evaluated in 40 patients with subclinical hypothyroidism (TSH 6.0-9.9mIU/L), 40 patients with overt hypothyroidism (TSH  $\geq 10.0$  mIU/L) between 20-50 years of age and were compared with 40 age matched normal euthyroid controls after applying exclusion criteria. Thyroid profile and LFT were estimated using fully autoanalyser VITROS 5600 considering p value  $<0.05$  as significant.

**Results and observations:** Subjects with both subclinical hypothyroidism and overt hypothyroidism had significantly raised serum AST, ALT, ALP ( $P<0.0001$ ) and total protein levels ( $P<0.01$ ) compared to controls. Further, TSH showed significant positive correlation with AST, ALT and ALP ( $P<0.05$ ) in both subclinical and overt hypothyroidism whereas FT3 and FT4 had a significant negative correlation with AST, ALT and ALP ( $P<0.05$ ) in overt hypothyroidism.

**Conclusion:** It might be necessary to monitor liver enzymes frequently in hypothyroid patients as declining liver function may be missed by single assessment and deranged biochemical parameters of LFT might indicate underlying altered thyroid status.

**Key words-** LFT, FT3, FT4, TSH

---

### **Introduction:**

The thyroid gland synthesizes and releases triiodothyronine (T3) and thyroxine (T4), which represent the only iodine containing hormones in the vertebrates. T3 is the biologically active thyroid hormone<sup>(1)</sup>. The major secretory product of the thyroid is a prohormone (T4), which is activated in peripheral tissues by outer ring deiodination to T3. There are three homologous iodothyronine deiodinases which catalyses these reactions<sup>(2),(3)</sup>.

Type I deiodinase is located in liver, kidney, and thyroid. In addition to that, the liver has an important role in thyroid hormone transport and metabolism. These hormones are required for the normal growth, development and function of nearly all tissues, with major effects on oxygen consumption and metabolic rate<sup>(4)</sup>. Thyroid hormone synthesis and secretion is regulated by a negative feedback system that involves the hypothalamus, pituitary, and the thyroid gland<sup>(5)</sup>.

The free, unbound component of thyroid hormone within plasma is in equilibrium with the protein-bound hormone and accounts for its biological activities. Though tissues are exposed to the same plasma concentrations of free T4 and T3 free hormone, their concentrations in different tissues vary according to the transport and deiodinase activity within specific tissues<sup>(6)</sup>. Thyroid hormones regulate the basal metabolic rate of all cells including hepatocytes. The liver in turn metabolizes the thyroid hormones and regulates their systemic endocrine effects<sup>(7)</sup>. Thyroid hormones are glucuronidated and sulphated within the liver and subsequently excreted into bile; in addition, these hormones maintain the metabolism of bilirubin by playing a role in the enzymatic activity of glucuronyltransferase and by regulating the level of ligandin, a major organic anion-binding protein<sup>(8)</sup>. In fact, there are several clinical and laboratory associations between thyroid and liver diseases namely-

- (i) Liver damage secondary to the systemic effect of thyroid hormone excess or direct toxic effects and subclinical physiological effects of thyroid hormone on liver functions.
- (ii) Some patients with chronic liver diseases may have thyroiditis, hyperthyroidism or hypothyroidism through autoimmune mechanisms.
- (iii) Alterations of thyroid hormone metabolism or tests secondary to liver disease, and
- (iv) Liver or thyroid disorders related to the therapy of thyroid or liver disease.

Therefore, it is not surprising that hepatic dysfunction is commonly observed in patients with thyroid disease. Thus, the interpretation of thyroid function tests in patients with liver disease as well as the interpretation of liver bio-chemical tests in patients with thyroid disease must take these facts

into account if errors in patients care are to be avoided<sup>(9-12)</sup>.

The thyroid frequently is a common target of disease or dysfunction<sup>(13)</sup>. Thyroid disorders are commonly separated into two major categories, hyperthyroidism (caused by an overactive thyroid gland) and hypothyroidism (due to a poorly functioning thyroid gland), depending on whether serum thyroid hormone levels (T4 and T3) are increased or decreased, respectively. Both hypothyroidism and hyperthyroidism have potentially fatal systemic manifestations<sup>(14)</sup>.

Thyroid hormones are essential for normal organ growth, development, function and regulation of the basal metabolic rate of all cells and therefore, its alteration can affect the entire metabolism<sup>(15)</sup>. Most affected organs include liver and heart. So, it alters the liver enzymes like ALP, AST, ALT, GGT and cardiac enzymes like CPK, LDH and AST<sup>(16, 17, 18)</sup>. ALT may also be elevated occasionally and cholesterol elevation is as a rule due to hypometabolism. The later may result in fatty liver causing mild but prolonged AST and/or ALT elevation, and therefore, be erroneously considered chronic hepatitis, particularly before the advent of hepatitis C virus assays. These biochemical changes, usually mild, are also reversible with adequate thyroid replacement therapy<sup>(19)</sup>.

There is also evidence that hypothyroidism may directly affect the liver structure or function. Hypothyroidism has been associated in a few case reports with cholestatic jaundice attributed to reduced bilirubin and bile excretion. In experimental hypothyroidism, the activity of bilirubin UDP-glucuronyltransferase is decreased, resulting in a reduction in bilirubin excretion<sup>(20)</sup>. The reduction in bile flow may be in part due to an increase in membrane cholesterol-phospholipid ratio and diminished membrane fluidity<sup>(20)</sup> which may affect a number of canalicular membrane

transporters and enzymes, including the Na<sup>+</sup>-K<sup>+</sup>-ATPase.

The triad of reduced bilirubin excretion, hypercholesterolaemia and hypotonia of the gall bladder seen in hypothyroidism increases the incidence of gallstones<sup>(21)</sup>. Recent studies have shown that the hepatic abnormalities associated with hypothyroidism can be reversible over a matter of weeks with thyroxine replacement, with no residual liver damage<sup>(22,23)</sup>. So, it is evident that thyroid dysfunction may affect liver function and liver disease modulates thyroid hormone metabolism, and a variety of systemic diseases affect both organs.

#### **Aims and objectives:**

Present study was done to evaluate the biochemical parameters of thyroid function test (FT3, FT4, TSH) and liver function test among known hypothyroid patient and healthy control as well as to find any possible correlation among the measured parameters under study.

#### **Materials and methods:**

An analytical cross-sectional study was conducted on subjects of age group between 20-50 yrs attending out patient department (OPD) of Gauhati Medical College & Hospital after taking approval from institutional ethics committee. Total no of 40 patients with diagnosed subclinical hypothyroidism and 40 patients with diagnosed overt hypothyroidism each, coming for thyroid function test were enrolled in the study and compared with 40 age matched normal euthyroid controls. Informed consent duly signed by each of the participants was taken. Thyroid profile tests (FT3, FT4 and TSH) were estimated to categorize subclinical hypothyroidism and overt hypothyroidism. Subjects were divided into two groups, test group1 and test group 2.

1) **Test group 1-** consists of 40 patients with subclinical hypothyroidism (**TSH 6.0-9.9 mIU/L**)

2) **Test group 2-** consists of 40 patients with overt hypothyroidism (**TSH ≥10.0 mIU/L**)

Biochemical parameters of liver function test (total bilirubin, AST, ALT, ALP, total protein, albumin) were estimated in subclinical hypothyroids, overt hypothyroids and in healthy controls. Patients with history of diabetes mellitus, renal disorders, active infection or a recent infection, liver disease, bone and muscle disease, cardiac disease, pancreatic disease, hypertension, malignancy, taking oral contraceptive pills (OCP), pregnancy, alcoholics, and drug abusers were excluded from the study group.

Taking aseptic and antiseptic precautions, about 5 ml of fasting blood was collected by venous puncture and transferred to appropriate sterile vial. Serum obtained after centrifugation was separated into two aliquots-one for estimation of Liver Function test and other for estimation of thyroid function test and were analysed immediately after separation using fully automated analyzer (VITROS-5600). FT3, FT4, TSH were estimated by Chemiluminescence method<sup>(24)</sup>, total bilirubin (TBil) was estimated by Jendrassik-Grof method<sup>(25)</sup>, aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) were estimated using IFCC recommended methods<sup>(26,27,28)</sup>, total protein(TP) was estimated by biuret method<sup>(29)</sup> and albumin was estimated by modified bromocresol green method<sup>(30)</sup>.

**Statistical analysis**

Data were expressed as **mean ± SD**. ANOVA tests were used to analyze differences in baseline characteristics and biochemical parameters between the control and the test groups. Correlations were observed by using Pearson’s correlation coefficient and probability (p value) < **0.05** was considered significant. Statistical analysis was done using GraphPad InStat version 3.00. All the statistical graphs were prepared using Microsoft Excel 2007.

**Observations and results**

In the control group, comprising of 40 individuals, the mean±SD of age was **34.2 ±6.68** years. In test group1, comprising of 40 individuals, the mean±SD of age of the subjects was **35.05±7.15** years while in overt hypothyroidism (test group2), the mean±SD of age of the subjects was **33.45 ±4.92** years (**table1, fig 2**).

On comparing the baseline characteristics, we did not find any significant difference in mean level of age (**p=0.726**) and sex ratio (**p=0.648**) between control group and the test groups (**table 3**). However, mean of FT3, FT4 and TSH levels decreased in both test group1 and test group2 when compared with controls with p value found to be extremely significantly (**p<0.0001**) (**table 3, fig 4-6**) We also found that the mean of AST, ALT and


ALP levels increased in both test group1 and test group2 when compared with healthy controls with p value again found to be extremely significantly (**p<0.0001**)(**table 3, fig 7-9**). Similarly, the mean of total protein levels of both test group 1 and test group 2 were found to be increased significantly when compared with controls (**p=0.0011**)(**table 3, fig 10**). However, we did not find any significant difference of mean total bilirubin and albumin levels (**p=0.093** and **p=0.074**) when both test group 1 and test group 2 were compared with normal healthy controls.

On observing correlation using Pearson’s correlation coefficient, we found that TSH levels showed highly significant positive correlation with AST (**p<0.0001**), ALT (**p<0.0001**) and significant positive correlation with ALP levels (**P<0.05**) in subjects with subclinical hypothyroidism (**table 11, fig 13,14**). TSH levels also showed highly significant positive correlation with AST (**p=0.0002**), ALT (**p<0.0001**) and ALP levels (**P<0.0001**) in subjects with overt hypothyroidism (**table 12, fig 15,16**). Moreover, FT3 and FT4 levels had a significant negative correlation with AST, ALT and ALP levels (**P<0.05**) in overt hypothyroidism (**table 11,12**).

STATISTICS	CONTROL	TEST GROUP1	TEST GROUP2
N	40	40	40
MEAN	34.2	35.05	33.45
MEDIAN	33.5	35	34
SD	6.68	7.15	4.92
RANGE	20-50	20-50	20-50

**Table1: Showing comparison of the statistics of ages in the study groups**


**Fig 2: Showing mean of ages in the studied groups**




PARAMETERS (NORMAL RANGE)	CONTROL (n=40) Mean± SD	TEST GROUP1 (n=40) Mean± SD	TEST GROUP2 (n=40) Mean± SD	P value
AGE (Years)	34.2±6.68	35.05±7.15	33.45±4.92	0.726
SEX (M/F)	22/18	19/21	18/22	0.648
FT3 (4.26-8.10pmol/L)	5.56±0.756	4.38±0.447	3.75±0.558	<0.0001**
FT4 (10-28.2pmol/L)	14.01±1.805	10.81±0.985	8.91±0.46	<0.0001**
TSH (0.465- 4.68mIU/L)	2.39±1.20	7.72±1.56	20.09±10.24	<0.0001**
T.BILIRUBIN(0.2-1.3mg/dl)	0.68±0.159	0.69±0.177	0.76±0.171	0.093
AST (17-59U/L)	42.58±11.99	60.87±11.62	90.43±24.84	<0.0001**
ALT (21-72U/L)	45.99±11.86	65.92±5.71	90.38±24.01	<0.0001**
ALP (38-126U/L)	95.18±19.27	151.13±34.26	165.13±25.51	<0.0001**
T. PROTEIN(6.4-8.3g/dl)	7.22±0.523	7.52±0.542	7.56±0.591	0.0011*
ALBUMIN (3.5-5.0g/dl)	4.51±0.373	4.54±0.284	4.65±0.291	0.074

**Table 3: shows comparison between the baseline and biochemical characteristics of the studied groups. Anova test used for comparison of means between the three groups. \*\*denotes extremely significant and \* denotes highly significant p values when test groups were compared with controls.**


**Fig 4: Showing means of FT3 in the studied groups**




**Fig 5: Showing means of FT4 in the studied groups**




**Fig 6: Showing means of TSH in the studied groups**



**Fig 7: Showing means of AST in the studied groups**



**Fig 8: Showing means of ALT in the studied groups**



**Fig 9: Showing means of ALP in the studied groups**





Fig 10: Showing means of Total protein in the studied groups



PARAMETERS	TOTAL BILIRUBIN	AST	ALT	ALP	TOTAL PROTEIN	ALBUMIN
FT3	r=-0.044 p=0.812	r=-0.044 p=0.789	r=-0.0493 p=0.765	r=-0.079 p=0.629	r=-0.0386 p=0.815	r=-0.125 P=0.444
FT4	r=0.208 p=0.260	r=0.0121 p=0.941	r=0.140 p=0.392	r=0.092 p=0.576	r=0.0695 p=0.674	r=0.0673 p=0.683
TSH	r=-0.092 p= 0.514	r=0.805** p<0.0001**	r=0.354** p<0.0001**	r=0.651** P<0.05*	r=-0.0043 p=0.891	r=0.2875 P=0.245

Table 11: Showing correlations between thyroid profile and LFT in subclinical hypothyroidism. \*

denotes significant and \*\* denotes highly significant p values.

PARAMETERS	TOTAL BILIRUBIN	AST	ALT	ALP	TOTAL PROTEIN	ALBUMIN
FT3	r=0.310 P=0.061	-0.344* P=0.031*	r= -0.415* p=0.007*	r= -0.323* p=0.04*	0.083	0.226
FT4	r=0.0133 P=0.941	-0.547* P<0.05*	-0.485* P<0.05*	-0.247* P<0.05*	0.095	0.253
TSH	r=-0.0036 p=0.983	r=0.557** p=0.0002**	r=0.612** p<0.0001**	r= 0.579** p<0.0001**	r= 0.0878	r= -0.1066

Table 12: Showing correlations between thyroid profile and LFT in overt hypothyroidism \* denotes significant and \*\* denotes highly significant p value.



Fig 13: Showing Pearson's correlation between TSH and AST in test group1.




Fig 14: Showing Pearson's correlation between TSH and ALT in test group1.






Fig 15: Showing Pearson's correlation between TSH and ALT in test group2.



**Fig 16– Showing Pearson’s correlation between TSH and ALP in test group2.**



### Discussion

The data presented here shows that there is a significant increase in biochemical parameters of liver function test in hypothyroid patients when compared to normal controls. All these findings clearly suggest that biochemical markers of liver may be affected by alteration in the thyroid hormone levels in the body. Our data showed a significant increase in AST, ALT, ALP and total protein levels in hypothyroid patients when compared to healthy controls and this increase was also significant when overt hypothyroid patients were compared with subclinical hypothyroid patients. The findings of our study is in corroboration with findings of the study by **Yadav A. et al.<sup>(31)</sup>** and **Pandey R. et al.<sup>(32)</sup>**. **Malik and Hodgson et al** also mentioned that thyroid hormones T3 and T4 regulate BMR of hepatocytes and modulate all the organ functions. The liver, muscle and kidney in turn metabolizes thyroid hormones and regulates their systemic endocrine effects. Therefore, thyroid dysfunction may disturb liver, muscle and other organ functions and vice versa<sup>(7)</sup>.

In our study TSH level showed significant positive correlation with AST, ALT and ALP and total protein levels in both subclinical and overt hypothyroidism whereas FT3 and FT4 levels had a significant negative correlation with AST, ALT and ALP levels in overt hypothyroidism.

The significant positive correlation of TSH levels with levels of ALT in both patients with subclinical hypothyroidism (test group 1) (**p<0.0001**) and over hypothyroidism (test group 2) (**p<0.0001**) in our study may be explained by the observations made by **Targhar G. et al.<sup>(16)</sup>**, **Khan T. et al.<sup>(17)</sup>** and **Prakash A. et al.<sup>(18)</sup>** that thyroid alteration effects the liver enzymes like ALP, AST and ALT. **Couzigou P et al.<sup>(19)</sup>** also found that ALT may also be elevated occasionally and cholesterol elevation is as a rule due to hypometabolism. The later may result in fatty liver causing mild but prolonged AST and/or ALT elevation. The significant positive correlation of TSH levels with AST levels in both subclinical and overt hypothyroid subjects (**p<0.0001** and **p=0.0002** respectively) may be because of myopathy associated with hypothyroidism. The significant positive correlation of serum TSH levels with ALP in both

subclinical ( $p < 0.05$ ) and overt hypothyroidism ( $p < 0.0001$ ) may be explained on the basis observations of **Klion F et al.** that in hypothyroidism there is an increase in membrane cholesterol phospholipid ratio and diminished membrane fluidity, which affect a number of canalicular membrane transporters and enzymes, including the  $\text{Na}^+$ ,  $\text{K}^+$ -ATPase resulting in the change of ALP enzymes<sup>(20)</sup>.

Serum total protein also demonstrated a statistically significant increase in hypothyroid subjects when compared with normal controls. However correlation of serum albumin with thyroid profile was not found to be statistically significant. This indicates that probably in hypothyroidism, proteins other than albumin may be synthesized by the liver including a number of plasma proteins that bind the lipophilic thyroid hormones. Added to this, low-grade inflammation associated with even mild degrees of hypothyroidism may lead to a resultant increase in inflammatory proteins and immunoglobulins<sup>(33)</sup>.

In few case reports, hypothyroidism has been associated with cholestatic jaundice attributed to reduced bile excretion<sup>(21)</sup>. But our study did find any significant increase in total bilirubin level

when hypothyroid subjects were compared with normal healthy controls may be due to selective data of referral cases from OPD.

**Limitations of the study :** Small sample size was the limitation of our study.

#### **Conclusion**

To conclude, the present study indicates that thyroid disorder might cause significant effect on metabolism of various cells including hepatocytes reflected by increase in biochemical parameters of liver function test and it's significant correlation with components of thyroid profile test (FT3, FT4 and TSH) in both subclinical and overt hypothyroid subjects. Therefore, might be essential to measure liver function test in hypothyroid patients to know the association between thyroid alteration and deranged biochemical parameters of liver function. It might be necessary to monitor liver enzymes frequently in hypothyroid patients as declining liver function may be missed by single assessment and deranged biochemical parameters of liver function test (LFT) might indicate underlying altered thyroid status. However, further studies are required to be carried out in large sample size to confirm our findings.

#### **References:**

1. Boelaert K, Franklyn JA. Thyroid hormone in health and disease. *J Endocrinol.* 2005;187: p.1-15.
2. Larsen PR, Berry MJ. Nutritional and hormonal regulation of thyroid hormone deiodinases. *Annu Rev Nutr.* 1995;15:p.323-52.
3. Visser TJ. Pathways of thyroid hormone metabolism. *Acta Med Austr.* 1996;23:p.10-11.
4. Malik R, Hodgson H. The relationship between the thyroid gland and the liver. *Q J Med.* 2002;95:p.559-69.
5. Shupnik MA, Ridgway EC, Chin WW. Molecular biology of thyrotropin. *Endocr Rev.* 1989; 10: p.459-75.
6. Bianco AC, Salvatore D, Gereben B, et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. *Endocr Rev.* 2002;23:p.38-89.
7. Malik R, Hodgson H. The relationship between the thyroid gland and the liver. *Q J Med.* 2002; 95: p.559-69.
8. Fagioli S, Van Thiel DH. The liver in endocrine disorders. In: Rustgi VK, Van Thiel DH, eds. *The Liver in Systemic Disease.* New York, New York: Raven Press; 1993:p.285-287.

9. Babb R.R. Associations between diseases of the thyroid and the liver. *Am.J. Gastroenterol.* 1984; 79: p.421-3.
10. Salata R., Klein I., Levey G. Thyroid hormone homeo-stasis and the liver. *Semin. Liver Dis.* 1985; 5: p.29-34.
11. Fong T.L., Mchutchison J.G., Reynolds T.B. Hyperthyroidism and hepatic dysfunction: A case series analysis. *Clin. Gastroenterol.* 1992; 14: 240-4.
12. Huang M.J., Li K.L., Wei J. S., Wu S.S., Fank D., Liaw Y.F. Sequential liver and bone biochemical changes in hyperthyroidism: Revisited by a prospective controlled follow-up study. *Am. J. Gastroenterol.* 1994; 89: p.1071-6.
13. Shomon M.J. *Guide to Thyroid Disease*. 2010 edition, Kensington, MD 20895-0565- 888-810-9471.
14. Kumar V, Abbas AK, Fausto N, Mitchell. chapter-Diabetes mellitus. In Robbin's Basic Pathology.8th ed. Philadelphia, New-York: Elsevier Saunders(2007) p.-758
15. Mittal A, Sathian B, Kumar A, *et al.*, The Clinical implications of thyroid hormones and its association with lipid profile: A comparative study from western Nepal, *Nepal Journal of Epidemiology.* 2010; 1 (1): p.11–16.
16. Targher G., Montagnana M., Salvagno G. *et al.* Association between serum TSH, free T4 and serum liver enzyme activities in a large cohort of unselected outpatients. *Clin Endocrinol.* 2008; 68(3): p.481–484.
17. Khan T.M., Malik S, Diju I.U. Correlation between plasma thyroid hormones and liver enzymes level in thyrotoxic cases and controls in Hazara division. *J Ayub Med Coll Abbottabad.* 2010; 22(2): p.176–179.
18. Prakash A., Lal A.K., Negi K.S. Serum Creatine Kinase activity in thyroid disorders. *J Med Edu Research* 2007; 9(1): p.25–26.
19. Couzigou P, Latapie J.L, Fleury B. *et al.* Evolution of serum gammaglutamyl transpeptidase activity in treated hyperthyroid and hypothyroid patients. *Gastroenterol Clin Biol.* 1985; 8(5): p.458–463.
20. Klion F.M., Segal R., Schaffner F. The effect of altered thyroid function on the ultrastructure of the human liver. *Am. J. Med.* 1971; 50: p.317-24.
21. Van Steenbergen W, Fevery J, De Vos R, Leyten R, Heirwegh KP, De Groote J. Thyroid hormones and the hepatic handling of bilirubin. I. Effects of hypothyroidism and hyperthyroidism on the hepatic transport of bilirubin mono- and diconjugates in the Wistar rat. *Hepatology.* 1989; 9: p.314–21.
22. Inkinen J, Sand J, Nordback I. Association between common bile duct stones and treated hypothyroidism. *Hepatogastroenterology.* 2000; 47:p.919–21.
23. Huang MJ, Liaw YF. Clinical associations between thyroid and liver diseases. *J Gastroenterol Hepatol.* 1995; 10: p.344–50.
24. Summers M *et al.* Luminogenic Reagent Using 3-Chloro 4-Hydroxy Acetanilide to Enhance Peroxidase/Luminol Chemiluminescence. *Clin Chem.* 41:S73; 1995.
25. Doumas B.T., Bayse D.D., *et al.* A candidate reference method for determination of bilirubin in serum. Test for transferability. *Clin. Chem.* 29; 297-301; 1983.
26. Bergmeyer H U, Horder M, Rej R. Approved Recommendation on IFCC Methods for the Measurement of Catalytic Concentration of Enzymes. Part 2. IFCC Method for Aspartate Aminotransferase. *J. Clin. Chem. Clin. Biochem.* 24:497– 510; 1986.
27. Bergmeyer HU, Horder M, Rej R. Approved Recommendation (1985) on IFCC Methods for the Measurement of Catalytic Concentration of Enzymes. Part 3. IFCC Method for Alanine Aminotransferase. *J. Clin. Chem. Clin. Biochem.* 24:481; 1986.

28. Tietz NW, Rinker AD, Shaw L M. IFCC Methods for the Measurement of Catalytic Concentration of Enzymes, Part 5. IFCC Method for Alkaline Phosphatase. *J Clin. Chem., Clin. Biochem.* 21:731–748; 1983.
29. Dumas BT, *et al.* A Candidate Reference Method for Determination of Total Protein in Serum: 1. Development and Validation. *Clin. Chem.* 27:1642–1650; 1981.
30. Corcoran RM, Durnan SM. Albumin Determination by a Modified Bromocresol Green Method. *Clin. Chem.* 23(4):765; 1977.
31. Yadav A., Arora S., Saini V., Arora MK., Singh R., Bhattacharjee J. Influence of thyroid hormones on biochemical parameters of liver function: a case-control study in North Indian population. *Internet Journal of Medical Update.* 2013;8(1): P.4-8
32. Pandey R., Jaiswal S., Sah JP., Bastola K., Dulal S. Assessment of Serum Enzymes Level in Patients with Thyroid Alteration Attending Manipal Teaching Hospital, Pokhara. *Research and Reviews: A Journal of Life Sciences.* 2013;3(1), P.1-9.
33. Gaitan E, Cooper DS. Primary hypothyroidism. *Curr ther endocrinol metab.* 1997;6: p.94-98.